Trial Profile
A retrospective observational cohort study evaluating influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who receive second-line immunotherapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jul 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine
- Indications Bladder cancer; Carcinoma; Renal cancer; Ureteral neoplasms; Urogenital cancer
- Focus Therapeutic Use
- 14 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology